Subjects who have received drugs that directly or indirectly inhibit calcineurin or Nuclear Factor of activated T cells (NFAT) activity .
Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to:
Pregnant or lactating as the treatments used in this study includes drugs that are FDA Pregnancy Category D.
Concurrent therapy with drugs active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir); participants must be off treatment with these agents for at least  days prior to surgery
Concurrent use of any of the following food or drugs within  days prior to the first dose of lorlatinib or crizotinib.
Participant requires treatment with concomitant drugs that target serotonin -hydroxytryptamine receptor  (HTR) or -hydroxytryptamine receptor B (HTBR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.
Participant requires treatment with concomitant drugs that target serotonin HTR or HTBR or sigma nonspecific receptor with the exception of drugs that are considered by the investigator to be absolutely essential for the care of the participant and for which no acceptable alternative exists.
History of any of the following within the last  months before administration of the first dose of the study drugs:
Use of drugs that might pose a risk of a drug-drug interaction within - days before the start of study therapy.
Participants with known addiction to any drugs
Taking other immunosuppressant drugs for GVHD, including mTor inhibitors (Note: Only steroids, calcineurin inhibitors, and ECP are acceptable).
Participants with known addiction to any drugs
Any therapeutic antibody within  weeks of first dose of study drugs.
Any patients taking drugs that are known to have drug interactions with tamoxifen will not be included
Drugs which are exclusively or primarily eliminated by cytochrome P- isozyme A (CYP)A.
Drugs which are exclusively or primarily eliminated by UDP glucuronyltransferase A (UGT)A.
Use of the following drugs within  weeks of study drug administration:  alpha-reductase inhibitors (finasteride, dutasteride), estrogens, Cyproterone acetate, biologic, or other agents with anti-tumor activity against prostate cancer, and androgens (testosterone, dihydroepiandrosterone [DHEA], etc.)
Patients taking drugs leading to significant QT prolongation and unable to stop drugs prior to treatment
Concomitant medications: drugs that are considered category D (consider therapy modification) and X (avoid combination) using the Lexicomp database are prohibited; concomitant drugs that fall into categories A (no known interaction), B (no action needed) and C (monitor therapy) are allowed
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide. High dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs
Concurrent treatment with non-permitted drugs including herbal remedies with immunostimulating properties (for example, mistletoe extract) or known to potentially interfere with major organ function (for example, hypericin)
Taken drugs known to interact with Rapamune such as cyclosporine, diltiazem, erythromycin, ketoconazole (and other antifungals), nicardipine (and other calcium channel blockers), rifampin, verapamil within  days prior to enrollment
Known risk factors for ocular toxicity Exclusions Related to Autoimmune Conditions and Immunomodulatory Drugs
Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure.
Anticoagulant drugs (e.g., warfarin) that could not be withdrawn during the  days prior to the VTP procedure or antiplatelet drugs (e.g. aspirin) that could not be withdrawn during the  days prior to the VTP procedure and  days after VTP;
Within  days of the first dose of the study drugs: Platelets >= ,/L.
Unable to undergo an F-DOPA-PET scan (e.g., Parkinsons disease, taking anti dopaminergic, or dopamine agonist medication or less than  half-lives from discontinuance of dopamine agonists)\r\n* Note: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline); if a patient is on any of these drugs, list which ones on the On-Study form
Subjects taking drugs that interact with OATPB (an anion transporter), MRP (a multidrug resistant protein), and/or P-glycoprotein (P-Gp)
Must be on stable doses of any drugs affecting hepatic drug metabolism or renal drug excretion (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, barbiturates, diphenylhydantoin, narcotic analgesics, probenecid). Such drugs should not be initiated less than  days prior to Baseline/CD or at any time during study participation. Whenever possible, narcotic analgesic doses should be stable within  days prior to study entry and during the first cycle of therapy.
Drugs that potently inhibit or induce CYPA should be administered with caution
Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide; Note: high dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs
Prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine, or study drugs involved in this protocol, or to a monoclonal antibody or prior hypersensitivity to platinum-containing agents
Using drugs known to lower or increase levels of DHEA
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the study drugs; if such drugs have been used, patients must have discontinued these agents at least  weeks (or as noted below) prior to initiating study treatment; examples include:\r\n* STRONG CYPA inducers \r\n* Immunosuppressants (e.g., tacrolimus, leflunomide, tofacitinib, roflumilast, pimecrolimus)\r\n* NSAIDs\r\n** Note: NSAIDs must be discontinued within  days prior to initiating study treatment
Patients taking drugs leading to significant QT prolongation where the interaction is too great to proceed with romidepsin
Previous malignancy within  years of the first dose of study drugs, except tumors totally resected and/or not requiring therapy
Concomitant medications: the following drugs need to be stopped at the time of beginning therapy: patient cannot be on liver enzyme inducing anticonvulsants; patients must not have received growth factors to support the number or function of white cells or platelets within the past  days and pegfilgrastim within the past  days; patients must not be receiving any anti-thrombotic or anti-platelet agents; patient cannot be on drugs that cause significant prolonged QT (category I drug)
Other drugs permitted but use with caution include; drugs are not recommended but can be used with caution\r\n* Antacids: use of H blockers and proton pump inhibitors is not recommended; patients who require antacids should use short acting, locally active agents (e.g., Maalox, Mylanta etc.); however, these agents should not be taken within either  hours before or  hours after the dasatinib dose\r\n* Drugs prolong QT interval; erythromycin, clarithromycin, pentamidine, ondansetron, granisetron, and methadone
Planned ongoing treatment with other drugs thought to potentially adversely interact with study drugs; if such medications have been used, patients must be off of these agents for >=  weeks prior to initiation of treatment:\r\n* Anticoagulants at therapeutic doses\r\n* Immunosuppressants such as tacrolimus, leflunomide or tofacitinib, roflumilast, pimecrolimus
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide; high dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs
Cardiac disease (history of and/or active disease) that would preclude the use of any of the drugs included in the treatment regimen. This includes but is not confined to:
Patients who have had flu, hepatitis, or other vaccines within a month prior to initiation of study drugs
The patient is unable to sustain treatment with antiviral drugs due to drug associated toxicities (e.g. myelosuppression [ANC< ?l/ml without GCSF support] or nephrotoxicity [corrected creatinine clearance ?  ml/min/. m^ or serum creatinine >  mg/dl]) CMV infections are life threatening, and may involve multiple organ systems such as the lungs, liver, gastrointestinal tract, hematopoietic and central nervous systems. Antiviral drugs used for treatment may also compromise renal and hematopoietic function. Therefore, dysfunctions of these organs will not affect eligibility for this protocol.
Patients must be at least  weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophyllotoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocol
Patients being treated with certain drugs not acceptable while receiving CFI- fumarate.
**continued from above: Atrial fibrillation documented within  weeks prior to first dose of study drug; Patients who require treatment with concomitant drugs that prolong QT/QTc interval or strong CYPA inhibitors or inducers with the exception of antibiotics, antifungals, and antivirals that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject.
Prior therapy with any hypoxic cytotoxin (hypoxia-targeting drugs).
Current use of illicit drugs, glucocorticoids other than those necessary for concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing or immune-modulating drugs. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort.
Current treatment with the following antiarrythmic drugs: flecainide, moricizine or propafenone
Concurrent use of anti-seizure drugs, with the exception of gabapentin for treatment of neuropathy
Subjects taking disulfiram or disulfiram-like drugs;
Drugs that affect the CYPA systems are allowed and essential for cancer patients, including anti-fungals but should be used with caution.
Part : patients with Cut Down, Annoyed, Guilty and Eye Opener-Adapted to Include Drugs (CAGE-AID) ? 
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide
Drugs that strongly inhibit or potentiate cytochrome P, family , subfamily A, polypeptide  (CYPA):\r\n* During Phase I: patients who have received these drugs within  days or within  half-lives of the drug (whichever is longer) prior to study initiation will be excluded\r\n* During Phase II: these drugs should be avoided if possible
Patients currently being treated with quinacrine or drugs related to quinacrine
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide
Use of drugs that inhibit renal tubular secretion (e.g. probenecid and cimetidine) within  weeks before the start of study treatment
Chronic treatment with immunosuppressant drugs
Prior treatment with adenovirus-based drugs
Subject requires treatment with concomitant drugs that target serotonin -hydroxytryptamine receptor  (HTR) or -hydroxytryptamine receptor B (HTBR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
Discontinuation of all drugs used to treat underlying MF disease at least  days prior to baseline visit
The following drugs must be stopped > weeks prior to CTL infusion: salvage chemotherapy (e.g. clofarabine, cytosine arabinoside >  mg/m, anthracyclines, cyclophosphamide, methotrexate ?  mg/m), excluding the required lymphodepleting chemotherapy drugs
Any therapeutic antibody within  weeks of first dose of study drugs.
Seizures occurrence or the requirement of escalation (or addition) of anti-epileptic drugs
Taking any medication known to moderately or severely inhibit the CYPA isozyme or any drugs that are CYPA inducers (including anti-epileptic agents such as phenytoin). A stable regimen (?  weeks) of antidepressants of the SSRI class is allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine)
Subject requires treatment with concomitant drugs that target serotonin -hydroxytryptamine receptor  (HTR) or -hydroxytryptamine receptor B (HTBR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
QT prolonging drugs with a known risk to induce TdP
Is receiving concomitant treatment with drugs that may interact with capecitabine
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide
Patients presenting with an AHNMD requiring immediate cytoreductive therapy or targeted drugs (e.g. AML)
Use of erectile dysfunction drugs (e.g., Cialis, Viagra) within  days prior to treatment or during study
Patients receiving any drugs that have potential nephrotoxicity or ototoxicity (such as an aminoglycoside)
Subject requires treatment with concomitant drugs that target serotonin HTR or HTBR or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
Patient may not be taking any drugs that prolong the QT/QTc interval; if patient is on any of these drugs, patient may enroll in the study if the drugs can be discontinued for at least  half-lives prior to the first dose of tosedostat and capecitabine
Concomitant use of significant CYPA inhibitors unless able to be switched to a non-CYPA inhibiting medication\r\n* Caution should be used when administering study drugs to patients taking medications significantly metabolized by these enzymes; particular attention should be paid to patients receiving warfarin; patients should have coagulation parameters monitored regularly, and warfarin dose adjusted accordingly; if these drugs cannot be discontinued or replaced, enrollment may be allowed after discussion with MSK principle investigator (PI)
Use of any drugs with pro-cholinergic properties (e.g. donepezil)
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide; note: high dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs
Women taking drugs associated with a substantial risk of myopathy when co-administered with simvastatin are not eligible
Subject requires treatment with concomitant drugs that target serotonin HTR or HTBR receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
Patients may not be taking any concomitant drugs that are contraindicated based on the drug-interaction table
Patients who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide; high dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs
Participants with known addiction to any drugs
concurrent use of anti-coagulant drugs
Use of concomitant drugs that prolong QT/QTc interval are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient, but only if clinically indicated and must be fully documented.
Patients taking drugs leading to significant QT prolongation
Any patients planning to receive Avastin or any other anti-angiogenic drugs
Treatment with drugs interacting with S-, -FU, or cisplatin.
use of any ARI drugs within  months prior to enrollment such as Finasteride (Proscar) or Dutasteride (Avodart);
Use of drugs that might pose a risk of a drug-drug interaction within - days before the start of study therapy.
Use of drugs known to inhibit UDP glycosyltransferase  family, polypeptide A gene (UGTA), such as Atazanavir, Gemfibrozil, Indinavir, or Ketoconazole while on study treatment; (patients using these drugs must not take these drugs on the day study treatment begins and for the duration of study treatment)
Use of statin drugs or other medications known to associate with rhabdomyolysis; these drugs must be discontinued at enrollment
Taking any medication known to inhibit the CYPA isozyme or any drugs that are CYPA inducers (including phenytoin), or any drugs associated with torsades de pointes or known to prolong the QTc(f) interval within  weeks prior to Day  of treatment on study. A stable regimen of antidepressants of the SSRI class is allowed
. Prior treatment with drugs an FAK inhibitor.
On chronotropic drugs (acetylcholine, digoxin, diltiazem, verapamil, atropine, dopamine, dobutamine, epinephrine, isoproterenol)
Patients should NOT have had prior therapy for primary myelofibrosis. This includes treatment with cytoreductive drugs (Hydroxyurea), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), JAK inhibitors, or other therapies specifically for myelofibrosis. If they received these classes of drugs for indications other than PMF, treatment should be discontinued at least  weeks prior to randomization.
Patients taking substrates of CYPC should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with the study drugs
Able to abstain from taking prohibited drugs, either prescription or non- prescription, during the treatment phase of the study
Prior treatment with drugs of the immunotoxin class
Patients already taking class Ic or III antiarrhythmic drugs
Patients taking CYPD inhibitors should be carefully monitored, but these drugs are not necessarily contraindicated when used concomitantly with LBH
Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study
Subject requires treatment with concomitant drugs that target serotonin HTR or HTBR receptors or sigma nonspecific receptor, with the exception of drugs that are considered absolutely essential for the care of the subject.
Patients taking the following medications may experience QT/QTc interval prolongation and are not eligible for the trial - most anti-arrhythmia drugs (incl. amiodarone), erythromycin, quinolone antibiotics, ketoconazole, Zithromax, and phenothiazine and will be denied enrollment in the study. The possible interactions of these drugs and DM-CHOC-PEN have not been established. Patients receiving these drug will only be eligible if they discontinue the drugs and have an acceptable ECG.
Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of Cytochrome P-isozymeA (CYPA) with the exception of antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject
Subject required treatment with concomitant drugs that target serotonin HTR or HTBR receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
Patients taking drugs leading to significant QT prolongation
Anti-platelet drugs within  weeks prior to the first dose of study drug. Anti-platelet drugs are defined as any agent or combination of agents with clinically proven anti-thrombotic activity administered by any route with the purpose of affecting blood clotting ability of the subject.
Certain drugs or radiation within - weeks of enrollment
Patients who are on concomitant treatment with drugs that are contraindicated in this study and that cannot be discontinued within the time frames
Investigative drugs within  days
Must not be receiving tacrolimus or cyclosporine; use of H antagonists such as ranitidine, cimetidine and proton pump blockers such as omeprazole are permissible only in conjunction with corticosteroids in the setting of increased intracranial pressure or for spinal cord compression, as these drugs interfere with cytochrome P A (CYPA); if patients are given such drugs, they must be taken at least  hours after intake of everolimus
Use of H antagonists such as ranitidine, cimetidine and proton pump blockers such as omeprazole are permissible only in conjunction with corticosteroids in the setting of increased intracranial pressure or for spinal cord compression, as these drugs interfere with CYPA; if patients are given such drugs, they must be taken at least  hours after intake of everolimus
Patients on drugs that interfere with renal function or drugs that compete with tenofovir for active binding sites (i.e. intravenous cidofovir, acyclovir, ganciclovir, and valganciclovir)
Patients on drugs that may prolong the PR or QRS interval durations, such as any of the class I/sodium (Na+) channel blocking antiarrhythmic medications should be avoided (e.g. flecainide, procainamide, propafenone, quinidine)
Receiving elotuzumab and/or other study drugs at the time of signature of informed consent
Receiving one of the following drugs and cannot be discontinued at least  hours before starting therapy, including: pimozide, quinidine, astemizole, ergot alkaloids
Use of concomitant medications that substantially increase seizure risk; such drugs could include neuroleptics (ex. haloperidol, droperidol), clozapine, tricyclic antidepressants (ex. amoxapine, clomipramine), bupropion (particularly the immediate release -IR- formulation) donepezil, psychostimulants (ex. methylphenidate), theophylline and/or other drugs that reduce the seizure threshold; for individuals on any of these medicines, a study clinician will evaluate the drugs and doses to determine the risks and benefits; these will then be discussed with the individual's Primary Care Physician to determine if the individual should be excluded from the study
Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
Have received one or more of the following chemotherapy (CTX) drugs: taxanes or platinum compounds
Patients taking drugs leading to significant QT prolongation must have an ECG prior to each treatment
Have used marine omega- supplements at any time within previous  months (this includes prescription omega- drugs such as Lovaza)
Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
Are taking drugs known to interact with zileuton, including theophylline, warfarin, and propranolol
Individuals who have used photosensitizing drugs within the last  days prior to study enrollment, or who will be using a photosensitizing drug during the time of the study, will not be eligible
Drugs that interfere with mitochondrial function if they are unable to be discontinued  hours prior to MBT testing will be excluded for this test only but eligible for the rest of the protocol
Excessive use of acetaminophen or other potentially hepatotoxic drugs
No history of uncontrolled seizures after surgery for primary GBM (despite adequate antiepileptic therapy) or with need for concurrent administration of more than  antiepileptic drugs.
Patients taking bile acid binding drugs (such as cholestyramine and colestipol)
Unable to undergo an F-DOPA PET scan (e.g. Parkinsons disease, taking anti-dopaminergic, or dopamine agonist medication or less than  half-lives from discontinuance of dopamine agonists; NOTE: other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline; if a patient is on any of these drugs, list which ones on the on-study form
Unable to undergo an F-DOPA PET scan (e.g. Parkinsons disease, taking anti-dopaminergic, or dopamine agonist medication or less than  half-lives from discontinuance of dopamine agonists); NOTE: other potentially interfering drugs consist of: amoxapine, amphetamine, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline; if a patient is on any of these drugs, list which ones on the on-study form
Concurrent use of drugs that are sensitive CYPB substrates, such as bupropion, efavirenz should be used with caution
Subject requires treatment with concomitant drugs that target serotonin -hydroxytryptamine receptor  (HTR) or -hydroxytryptamine receptor B (HTBR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
Has a history of:\r\n* Neuropathy or numbness/tingling suspicious for neuropathy prior to the first dose of chemotherapy for ovarian cancer\r\n* History of prior treatment for other cancers that includes drugs known to cause neuropathy; these drugs include but are not limited to vinca-alkaloids, platinums, taxanes, bortizomib.\r\n* B deficiency\r\n* Known peripheral vascular disease\r\n* Chronic daily headache or headache more than  days of the month
Patient is taking any photosensitizing drugs
Ongoing or prior treatment with traditional disease-modifying anti-rheumatic drugs or biologic agents (RCT)
Treatment with QT-prolonging drugs with a risk of causing torsades de pointes (TdP. Participants taking drugs with a possible or conditional risk of QT prolongation or drugs that are to be avoided by participants with congenital long QT syndrome may be considered if on a stable dose, pending discussion and agreement between the investigator and the sponsor.
Initiation of new photosensitizing drugs within  days of Screening.
Unable to take drugs orally